☆ 4.5 Article

A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies

STATISTICS IN MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Infectious Diseases

UNITE4TB: a new consortium for clinical drug and regimen development for TB

M. J. Boeree et al.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2021)

Add to Collection

Article Microbiology

Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis

Andrew D. Gewitz et al.

Summary: This study aimed to establish a model describing longitudinal TTP, identify characteristics associated with delayed culture conversion time, and explore the factors affecting bacterial clearance by rifapentine. Sensitivity analysis revealed the potential for early detection of exposure-response relationships in phase 2b trials using truncated TTP data.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Mathematical & Computational Biology

A Markov chain approach for ranking treatments in network meta-analysis

Anna Chaimani et al.

Summary: In network meta-analysis, researchers acknowledge potential limitations in data and treatment comparisons that cannot be addressed through statistical analysis. A new measure called POST-R is proposed to aid treatment ranking in clinical practice by considering both NMA results and external information. This approach aims to provide rankings that inform decision-making more efficiently by representing relative effects and potential limitations.

STATISTICS IN MEDICINE (2021)

Add to Collection

Article Mathematical & Computational Biology

Using simulation studies to evaluate statistical methods

Tim P. Morris et al.

STATISTICS IN MEDICINE (2019)

Add to Collection

Article Pharmacology & Pharmacy

Robust Bayesian nonlinear mixed-effects modeling of time to positivity in tuberculosis trials

Divan Aristo Burger et al.

PHARMACEUTICAL STATISTICS (2018)

Add to Collection

Article Pharmacology & Pharmacy

A Bayesian paradigm for decision-making in proof-of-concept trials

Erik Pulkstenis et al.

JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2017)

Add to Collection

Article Immunology

Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials

Laura J. Bonnett et al.

CLINICAL INFECTIOUS DISEASES (2017)

Add to Collection

Article Medical Informatics

Bayesian Design of Proof-of-Concept Trials

Roland Fisch et al.

THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2015)

Add to Collection

Article Medicine, Research & Experimental

The utility of Bayesian predictive probabilities for interim monitoring of clinical trials

Benjamin R. Saville et al.

CLINICAL TRIALS (2014)

Add to Collection

Article Medicine, General & Internal

Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

Stephen H. Gillespie et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Pharmacology & Pharmacy

Dolutegravir: First Global Approval

Anita D. Ballantyne et al.

DRUGS (2013)

Add to Collection

Letter Medicine, General & Internal

Early bactericidal activity of new drug regimens for tuberculosis

Robert S. Wallis et al.

LANCET (2013)

Add to Collection

Article Multidisciplinary Sciences

An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse

Patrick P. J. Phillips et al.

PLOS ONE (2013)

Add to Collection

Article Infectious Diseases

Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents

A. H. Diacon et al.

CLINICAL MICROBIOLOGY AND INFECTION (2012)

Add to Collection

Review Mathematical & Computational Biology

Bayesian statistics in medicine: A 25 year review

Deborah Ashby

STATISTICS IN MEDICINE (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.